Compare ELOX & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELOX | DRIO |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 70.6M |
| IPO Year | 2013 | 2013 |
| Metric | ELOX | DRIO |
|---|---|---|
| Price | $15.31 | $6.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $38.25 | $13.60 |
| AVG Volume (30 Days) | ★ 21.4K | 14.9K |
| Earning Date | 08-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.67 | ★ 1559.02 |
| EPS | N/A | ★ 1.75 |
| Revenue | N/A | ★ $7,394,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $38.77 |
| P/E Ratio | ★ N/A | $3.78 |
| Revenue Growth | N/A | ★ 43.02 |
| 52 Week Low | $10.00 | $5.84 |
| 52 Week High | $23.40 | $17.74 |
| Indicator | ELOX | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 43.31 |
| Support Level | $13.92 | $6.49 |
| Resistance Level | $19.43 | $8.10 |
| Average True Range (ATR) | 1.39 | 0.25 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 23.89 | 1.69 |
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.